Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer
06 nov. 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer Phase 2 study to examine safety and efficacy of up to two...
Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting
11 mai 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting Rockville, Maryland, May...
Sunstone Therapies Announces Publication of Positive Data on Use of Psilocybin Therapy for Patients with Cancer and Major Depression Disorder, in JAMA Oncology
13 avr. 2023 11h16 HE
|
Sunstone Therapies
Phase 2 data shows sustained response in 80% of patients and 50% of patients in full remission of depressive symptoms Use of group setting and 1:1 patient to therapist ratio has...
Ketamine Media Scheduled to Launch North America's Largest Psilocybin Awareness Network
21 déc. 2022 10h30 HE
|
Ketamine Media
KNOXVILLE, Tenn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Ketamine Media announced today that it is in the final stages of launching its digital ecosystem of premium online properties to raise awareness...
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
28 juil. 2022 04h00 HE
|
COMPASS Pathways
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
23 mai 2022 07h00 HE
|
COMPASS Pathways
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
03 mai 2022 07h00 HE
|
COMPASS Pathways
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022 COMPASS...
COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
24 mars 2022 05h00 HE
|
COMPASS Pathways
Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust London, UK, 24 March 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”),...
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
19 janv. 2022 07h00 HE
|
COMPASS Pathways
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
04 janv. 2022 07h00 HE
|
COMPASS Pathways
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...